Short answer
Disc Medicine, Inc. (IRON) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$60M
- +4.5% YoY · −0.0% QoQ
- EPS (diluted)
- −$1.53
- +14.0% YoY · +0.6% QoQ
Source: XBRL data from the Disc Medicine, Inc. (IRON) Q3 2026 10-Q on SEC EDGAR. USD.
Disc Medicine, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales since inception
- Net loss $59.5M vs $62.3M YoY, operating expenses $64.2M vs $67.7M
- Best R&D performer: selcodebart expenses $8.4M, up $1.1M; lowest DISC-3405 at $4.9M, down $7.0M
- Cash, equivalents and securities $682.8M; October offering added approximately $485.9M net
- Operating cash outflow $146.6M through nine months; funding expected into 2030, APOLLO supports NDA resubmission by year-end 2026
Risk Factors
- Newly triggered supply-chain risk: BIOSECURE Act restrictions and China tariffs may disrupt foreign vendors, materials, and clinical trials
- Most material regulatory update: FDA’s February 2026 CRL rejected bitopertin accelerated approval, requiring APOLLO clinical-benefit evidence
- Near-term development risk: APOLLO topline results remain subject to FDA review before planned NDA resubmission by end-2026
- Financial risk: $200.0 million senior secured term loan matures December 1, 2029, with minimum qualified-cash covenant
- Liquidity risk: Management expects cash, cash equivalents, and marketable securities to fund operations into 2030, based on uncertain assumptions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Disc Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.